NCT06245915View on ClinicalTrials.gov

AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 26, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2028

Conditions
Advanced/Metastatic Clear Cell Renal Cell CarcinomaRecurrence
Interventions
BIOLOGICAL

AB-2100

autologous T cell therapy

Trial Locations (9)

10016

Perlmutter Cancer Center - NYU Langone Health, New York

10065

Memorial Sloan Kettering Cancer Center, New York

33612

Moffitt Cancer Center, Tampa

52242

University of Iowa and Holden Comprehensive Cancer Center, Iowa City

77030

MD Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute - Univ of Utah Health, Salt Lake City

85054

Mayo Clinic Hospital, Phoenix

91010

City of Hope, Duarte

02215

Dana Farber Cancer Institue, Boston

Sponsors
All Listed Sponsors
lead

Arsenal Biosciences, Inc.

INDUSTRY

NCT06245915 - AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) | Biotech Hunter | Biotech Hunter